A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer
Authors
Keywords
-
Journal
Targeted Oncology
Volume 12, Issue 4, Pages 463-474
Publisher
Springer Nature
Online
2017-06-07
DOI
10.1007/s11523-017-0502-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study
- (2017) Lucia Nogova et al. JOURNAL OF CLINICAL ONCOLOGY
- The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing
- (2015) T. Helsten et al. CLINICAL CANCER RESEARCH
- Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan–Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors
- (2015) Josep Tabernero et al. JOURNAL OF CLINICAL ONCOLOGY
- The prognostic significance of fibroblast growth factor receptor 4 in non-small-cell lung cancer
- (2015) Hong-ping Huang et al. OncoTargets and Therapy
- The Fibroblast Growth Factor signaling pathway
- (2015) David M. Ornitz et al. Wiley Interdisciplinary Reviews-Developmental Biology
- Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer
- (2015) Jinjia Chang et al. Oncotarget
- Prognostic role of FGFR1 amplification in early-stage non-small cell lung cancer
- (2014) N Cihoric et al. BRITISH JOURNAL OF CANCER
- FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study
- (2014) X Su et al. BRITISH JOURNAL OF CANCER
- Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma
- (2014) Akiko Kawano Nagatsuma et al. Gastric Cancer
- FGFR1 amplification is associated with poor prognosis and smoking in non-small-cell lung cancer
- (2014) An Na Seo et al. VIRCHOWS ARCHIV
- Fibroblast growth factor receptors, developmental corruption and malignant disease
- (2013) F. C. Kelleher et al. CARCINOGENESIS
- Integrative and Comparative Genomic Analysis of Lung Squamous Cell Carcinomas in East Asian Patients
- (2013) Youngwook Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Fibroblast growth factor receptor 1 (FGFR1) copy number is an independent prognostic factor in non-small cell lung cancer
- (2013) Thang N. Tran et al. LUNG CANCER
- Fibroblast Growth Factor Receptor 1 Amplification in Non-Small Cell Lung Cancer by Quantitative Real-Time PCR
- (2013) Shirish M. Gadgeel et al. PLoS One
- Pan-FGFR Inhibition Leads to Blockade of FGF23 Signaling, Soft Tissue Mineralization, and Cardiovascular Dysfunction
- (2013) Gina M. Yanochko et al. TOXICOLOGICAL SCIENCES
- Identification of Targetable FGFR Gene Fusions in Diverse Cancers
- (2013) Yi-Mi Wu et al. Cancer Discovery
- FGFR2 gene amplification and clinicopathological features in gastric cancer
- (2012) K Matsumoto et al. BRITISH JOURNAL OF CANCER
- Role of FGF23 in vitamin D and phosphate metabolism: Implications in chronic kidney disease
- (2012) L. Darryl Quarles EXPERIMENTAL CELL RESEARCH
- A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets
- (2012) Niantao Deng et al. GUT
- Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer
- (2012) Hans-Ulrich Schildhaus et al. MODERN PATHOLOGY
- Deep sequencing of gastric carcinoma reveals somatic mutations relevant to personalized medicine
- (2011) Joanna D Holbrook et al. Journal of Translational Medicine
- A Novel, Selective Inhibitor of Fibroblast Growth Factor Receptors That Shows a Potent Broad Spectrum of Antitumor Activity in Several Tumor Xenograft Models
- (2011) G. Zhao et al. MOLECULAR CANCER THERAPEUTICS
- Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer
- (2010) J. Weiss et al. Science Translational Medicine
- The FGF family: biology, pathophysiology and therapy
- (2009) Andrew Beenken et al. NATURE REVIEWS DRUG DISCOVERY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started